- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05905770
Do Alemtuzumab Levels Predict T Cell Chimerism After MSD SCT for SCD? (PREDICT)
Do Serum Alemtuzumab Concentrations Predict Donor T Cell Chimerism After Non-Myeloablative Matched Sibling Donor Stem Cell Transplantation in Sickle Cell Disease Patients
Rationale: Non-myeloablative allogeneic stem cell transplantation (SCT) has become a feasible curative treatment option for sickle cell disease (SCD) patients with an available matched sibling donor. Chemotherapy free conditioning with alemtuzumab and 3 Gy total body irradiation (TBI) is increasingly being used as preferred conditioning scheme for these patients. This regimen typically results in mixed donor chimerism and has only few toxic effects. However, the risk of graft failure (rejection) is still significant, with an occurrence of 13% in the latest series. Levels of T cell chimerism are crucial for the success of this kind of transplantation. A donor T cell level of at least 50% at 1-year post-transplantation seems to be sufficient to allow the discontinuation of immunosuppressive medication without risk of graft rejection. Low levels of alemtuzumab prior to or shortly after SCT are thought to facilitate rejection of the donor graft. Recently, a positive correlation between alemtuzumab levels on day+14 was found with levels of T cell chimerism +2 and +4 months post-transplantation in adult SCD patients receiving matched sibling donor SCT. However, in this study alemtuzumab levels prior to the infusion of hematopoietic stem cells and beyond day +28 post-transplantation were not measured. Furthermore, the alemtuzumab levels were measured in 2 patient groups undergoing two different conditioning regimens.
Here, the investigators aim to thoroughly investigate the correlation of alemtuzumab levels and T cell chimerism. This will be the first study involving SCD patients receiving matched sibling donor SCT with alemtuzumab/TBI conditioning that includes alemtuzumab level measurements before the infusion of hematopoietic stem cells and beyond 1-month post-transplantation. Findings from this study will improve the insights into the etiology of graft failure in these patients and might ultimately lead to a more personalized approach in dosing alemtuzumab in order to achieve a more robust and stable engraftment of donor hematopoietic stem cells.
Objectives: To investigate whether serum alemtuzumab concentrations are predictive of the robustness of engraftment in SCD patients undergoing a matched sibling donor transplantation with alemtuzumab/TBI conditioning resulting in mixed chimerism.
Study design: Prospective observational laboratory study. Serum alemtuzumab concentration will be measured at various time points before and after stem cell infusion (days -3, 0, +7, +14, +28, +60).
Study population: Adult SCD patients that are planned for a matched sibling donor transplantation with alemtuzumab/TBI conditioning at the Amsterdam UMC.
Main study parameters/endpoints: The correlation between serum alemtuzumab concentration and levels of donor chimerism. Secondary endpoints: correlation between serum alemtuzumab levels and patients with and without successful engraftment. Correlation of serum alemtuzumab levels and the dosing of alemtuzumab in mg/kg, number of patient lymphocyte count and total number of infused enucleated donor-derived cells.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Erfan Nur, MD, PhD
- Phone Number: 0031-20 - 4442604
- Email: e.nur@amsterdamumc.nl
Study Locations
-
-
-
Amsterdam, Netherlands, 1105AZ
- Recruiting
- Amsterdam Medical Centre
-
Contact:
- Erfan Nur, MD, PhD
- Phone Number: 0031-20-4442604
- Email: e.nur@amsterdamumc.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 16 years and older
- High performance liquid chromatography (HPLC) confirmed diagnoses of SCD (all genotypes)
- Planned for a non-myeloablative matched sibling donor SCT with alemtuzumab/TBI at the Amsterdam UMC
- Willing and able to provide written informed consent
Exclusion Criteria:
- No specific exclusion criteria
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Sickle cell disease patients aged 16 years and older with an available matched sibling donor.
Alemtuzumab 1mg/kg/TBI 3Gy conditioning
|
Alemtuzumab 1mg/kg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The correlation between serum alemtuzumab concentration and donor T cell chimerism.
Time Frame: +1 year post-transplantation
|
+1 year post-transplantation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
o The differences in serum alemtuzumab concentration at the various time points (T1-T7) between patients with and without successful engraftment. Successful engraftment is defined as donor T cell chimerism >50% at 1-year post-transplantation.
Time Frame: +1 year post-transplantation
|
+1 year post-transplantation
|
o The correlation between the dosing of alemtuzumab in mg/kg, the number of patient lymphocytes and alemtuzumab levels at the various time points (T1-T7).
Time Frame: +1 year post-transplantation
|
+1 year post-transplantation
|
o The correlation between total number of infused enucleated donor-derived cells and the amount of decrease of alemtuzumab levels before and after stem cell infusion (T2 and T3).
Time Frame: +1 year post-transplantation
|
+1 year post-transplantation
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Erfan Nur, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- METC 2022_0189
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Alemtuzumab Injection [Campath]
-
M.D. Anderson Cancer CenterWithdrawnLymphoma | Hodgkin's Disease
-
Northwestern UniversityGenzyme, a Sanofi Company; Millennium Pharmaceuticals, Inc.Completed
-
Genzyme, a Sanofi CompanyTerminatedHematologic MalignanciesUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyelodysplastic SyndromesUnited States
-
Dana-Farber Cancer InstituteBayer; Genzyme, a Sanofi CompanyCompleted
-
M.D. Anderson Cancer CenterLeudositeTerminatedLymphoma, B-Cell | Lymphoma, T-Cell | Lymphoma, Low-Grade | Leukemia, Lymphocytic, Acute | Leukemia, Lymphocytic, ChronicUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedT-LGL Lymphoproliferative DisordersUnited States
-
National Institute of Neurological Disorders and...Completed
-
Samuel Forrester Hunter, MD, PhDUnknownMultiple SclerosisUnited States
-
Ontario Clinical Oncology Group (OCOG)Sunnybrook Health Sciences Centre; Genzyme, a Sanofi CompanyCompletedAlemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas (ACCAPELA)Peripheral T-cell LymphomasCanada